Stockreport

BioXcel Therapeutics Completes Dosing Two Cohorts of Agitated Schizophrenia Patients with BXCL501 in a Phase 2 Efficacy Trial

BioXcel Therapeutics, Inc.  (BTAI) 
Last bioxcel therapeutics, inc. earnings: 11/14 07:00 am Check Earnings Report
PDF Total of 96 agitated patients and healthy volunteers have received multiple doses of BXCL501, a proprietary sublingual thin film On track to announce top line results f [Read more]